Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).

ABSTRACT: Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for Candida spp. and rezafungin. The activities of rezafungin and comparators against 2019 to 2020 invasive fungal isolates was evaluated by applying the new CLSI breakpoints. Rezafungin demonstrated potent activity against Candida albicans (MIC₅₀/MIC₉₀, 0.03/0.06 mg/L; 100.0% susceptible), Candida tropicalis (MIC₅₀/MIC₉₀, 0.03/0.06 mg/L; 100% susceptible), Candida glabrata (MIC₅₀/MIC₉₀, 0.06/0.06 mg/L; 98.3% susceptible), Candida krusei (MIC₅₀/MIC₉₀, 0.03/0.03 mg/L; 100% susceptible), and Can

SUBMITTER: Carvalhaes CG 

PROVIDER: S-EPMC9020363 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature